INTEGRAGEN (ALINT.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALINT - FR0010908723 - Common Stock
ALINT.PA Key Statistics, Chart & Performance
The current stock price of ALINT.PA is 0.1545 EUR. In the past month the price increased by 2.32%. In the past year, price decreased by -68.34%.
ALINT.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.28 | 47.84B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.16B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.67B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.98M | ||
| PHIL.MI | PHILOGEN SPA | 20.26 | 675.44M | ||
| IVA.PA | INVENTIVA SA | N/A | 691.48M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About ALINT.PA
Company Profile
IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Company Info
INTEGRAGEN
Genopole Campus 1 - Genavenir 8 5 Rue Henri Desbrueres
Evry ILE-DE-FRANCE FR
Employees: 44
Phone: 33160910900
INTEGRAGEN / ALINT.PA FAQ
What does ALINT do?
IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
What is the stock price of INTEGRAGEN today?
The current stock price of ALINT.PA is 0.1545 EUR. The price decreased by -1.9% in the last trading session.
Does INTEGRAGEN pay dividends?
ALINT.PA does not pay a dividend.
What is the ChartMill rating of INTEGRAGEN stock?
ALINT.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is INTEGRAGEN (ALINT.PA) stock traded?
ALINT.PA stock is listed on the Euronext Paris exchange.
What is the market capitalization of ALINT stock?
INTEGRAGEN (ALINT.PA) has a market capitalization of 1.04M EUR. This makes ALINT.PA a Nano Cap stock.
ALINT.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALINT.PA. When comparing the yearly performance of all stocks, ALINT.PA is a bad performer in the overall market: 98.17% of all stocks are doing better.
ALINT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALINT.PA. ALINT.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALINT.PA Financial Highlights
Over the last trailing twelve months ALINT.PA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.71% | ||
| ROE | -14.77% | ||
| Debt/Equity | 0.11 |